FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111328291> ?p ?o ?g. }

• W2111328291 endingPage "59" @default.
• W2111328291 startingPage "49" @default.
• W2111328291 abstract "The well-known side-effect profile of androgen-deprivation therapy (ADT) has significant quality-of-life (QoL) implications. Intermittent androgen deprivation (IAD) alternates androgen blockade with treatment cessation to allow hormonal recovery between treatment cycles, thus potentially improving tolerability and QoL. To evaluate available evidence regarding the efficacy and tolerability of IAD and assess its value in the treatment of prostate cancer (PCa). Key phase 2/3 clinical trials of IAD in PCa published within the last 10 yr were identified on Medline using the terms prostatic neoplasms [MeSH], intermittent androgen suppression, intermittent hormonal deprivation, intermittent androgen deprivation, and intermittent hormonal therapy. Abstracts from trials reported at 2008–2009 conferences were also included. Data from 19 phase 2 studies are discussed with respect to prostate-specific antigen values for treatment suspension/reinitiation, treatment regimens, cycle lengths, testosterone normalisation, and tolerability. Outcome data were promising: Most trials reported an improvement in QoL during the off-therapy periods. Interim data from eight phase 3 trials comparing IAD and continuous androgen deprivation (CAD) support the phase 2 results. IAD generally showed comparable efficacy to CAD with respect to various outcomes, including biochemical progression, progression-free survival, and overall survival. However, IAD was significantly better than CAD with respect to 3-yr risk of progression in one study, and it demonstrated tolerability benefits, particularly with respect to sexual function. Patients most likely to benefit from IAD and factors predictive of poor response are also discussed. IAD seems to be as effective as CAD while showing tolerability and QoL advantages, especially recovery of sexual potency; however, there are as yet insufficient data to determine whether IAD has the potential to prevent or reverse the long-term complications associated with ADT." @default.
• W2111328291 created "2016-06-24" @default.
• W2111328291 creator A5043570965 @default.
• W2111328291 date "2010-01-01" @default.
• W2111328291 modified "2023-10-16" @default.
• W2111328291 title "Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature" @default.
• W2111328291 cites W1692457515 @default.
• W2111328291 cites W1964353534 @default.
• W2111328291 cites W1965734230 @default.
• W2111328291 cites W1965860392 @default.
• W2111328291 cites W1969650233 @default.
• W2111328291 cites W1976887636 @default.
• W2111328291 cites W1979211241 @default.
• W2111328291 cites W1982166321 @default.
• W2111328291 cites W1982226750 @default.
• W2111328291 cites W1985164813 @default.
• W2111328291 cites W1990413669 @default.
• W2111328291 cites W1996215694 @default.
• W2111328291 cites W1996548473 @default.
• W2111328291 cites W1997165312 @default.
• W2111328291 cites W2000221209 @default.
• W2111328291 cites W2003917043 @default.
• W2111328291 cites W2008323299 @default.
• W2111328291 cites W2009034973 @default.
• W2111328291 cites W2010146889 @default.
• W2111328291 cites W2013354835 @default.
• W2111328291 cites W2017404949 @default.
• W2111328291 cites W2027501801 @default.
• W2111328291 cites W2029676564 @default.
• W2111328291 cites W2030196700 @default.
• W2111328291 cites W2031872385 @default.
• W2111328291 cites W2035256990 @default.
• W2111328291 cites W2035397440 @default.
• W2111328291 cites W2037777722 @default.
• W2111328291 cites W2043929921 @default.
• W2111328291 cites W2054754562 @default.
• W2111328291 cites W2060090463 @default.
• W2111328291 cites W2060318706 @default.
• W2111328291 cites W2065213845 @default.
• W2111328291 cites W2070515287 @default.
• W2111328291 cites W2072158142 @default.
• W2111328291 cites W2074528665 @default.
• W2111328291 cites W2075512338 @default.
• W2111328291 cites W2078332534 @default.
• W2111328291 cites W2086580973 @default.
• W2111328291 cites W2092917417 @default.
• W2111328291 cites W2112304044 @default.
• W2111328291 cites W2117167667 @default.
• W2111328291 cites W2118458111 @default.
• W2111328291 cites W2132315278 @default.
• W2111328291 cites W2135078918 @default.
• W2111328291 cites W2136034669 @default.
• W2111328291 cites W2140081134 @default.
• W2111328291 cites W2155844247 @default.
• W2111328291 cites W2156351746 @default.
• W2111328291 cites W2158775552 @default.
• W2111328291 cites W2159437944 @default.
• W2111328291 cites W2163019678 @default.
• W2111328291 cites W2164194457 @default.
• W2111328291 cites W2166876116 @default.
• W2111328291 cites W2410165097 @default.
• W2111328291 cites W24933512 @default.
• W2111328291 cites W4230246781 @default.
• W2111328291 doi "https://doi.org/10.1016/j.eururo.2009.07.049" @default.
• W2111328291 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19683858" @default.
• W2111328291 hasPublicationYear "2010" @default.
• W2111328291 type Work @default.
• W2111328291 sameAs 2111328291 @default.
• W2111328291 citedByCount "168" @default.
• W2111328291 countsByYear W21113282912012 @default.
• W2111328291 countsByYear W21113282912013 @default.
• W2111328291 countsByYear W21113282912014 @default.
• W2111328291 countsByYear W21113282912015 @default.
• W2111328291 countsByYear W21113282912016 @default.
• W2111328291 countsByYear W21113282912017 @default.
• W2111328291 countsByYear W21113282912018 @default.
• W2111328291 countsByYear W21113282912019 @default.
• W2111328291 countsByYear W21113282912020 @default.
• W2111328291 countsByYear W21113282912021 @default.
• W2111328291 countsByYear W21113282912022 @default.
• W2111328291 countsByYear W21113282912023 @default.
• W2111328291 crossrefType "journal-article" @default.
• W2111328291 hasAuthorship W2111328291A5043570965 @default.
• W2111328291 hasConcept C121608353 @default.
• W2111328291 hasConcept C126322002 @default.
• W2111328291 hasConcept C143998085 @default.
• W2111328291 hasConcept C197934379 @default.
• W2111328291 hasConcept C2777899217 @default.
• W2111328291 hasConcept C2778311097 @default.
• W2111328291 hasConcept C2778375690 @default.
• W2111328291 hasConcept C2779322244 @default.
• W2111328291 hasConcept C2780192828 @default.
• W2111328291 hasConcept C535046627 @default.
• W2111328291 hasConcept C71924100 @default.
• W2111328291 hasConceptScore W2111328291C121608353 @default.
• W2111328291 hasConceptScore W2111328291C126322002 @default.
• W2111328291 hasConceptScore W2111328291C143998085 @default.
• W2111328291 hasConceptScore W2111328291C197934379 @default.

• next